Aribio Becomes Largest Shareholder of Aribio Lab... KRW 18 Billion Investment to Kick Off Bio Synergy

Aribio and Aribio Holdings are strengthening the unity of their group's bio business by investing a total of KRW 18 billion into Aribio Lab.

According to a disclosure by the Financial Supervisory Service on September 17, Aribio and Aribio Holdings will each invest KRW 15 billion and KRW 3 billion, respectively, as part of Aribio Lab's third-party paid-in capital increase. Once the capital increase is completed, Aribio will secure a 15.9% stake to become the largest shareholder, while Aribio Holdings will hold a 14.1% stake, making it the second-largest shareholder. Together, the two companies will hold a combined stake of 30%.

This investment is also expected to strengthen the research and development collaboration between Aribio and Aribio Lab. Aribio has accumulated drug development experience and built a global research network through global Phase III clinical trials for its oral Alzheimer’s treatment, AR1001. Aribio Lab, on the other hand, has established R&D capabilities in vaccines and immunity based on its proprietary immunostimulatory platform.

AR1001 is set to reveal results from its global Phase III trials. The partnership and capital investment between Aribio, which leads global new drug development, and Aribio Lab, which has vaccine and immune platforms, are expected to be further strengthened.

The two companies recently launched joint R&D for an Alzheimer’s vaccine, marking a full-scale partnership. Aribio Lab is currently conducting domestic Phase II clinical trials of the shingles vaccine “CVI-VZV-001,” which uses its proprietary immunostimulatory platforms “L-pampo™” and “Lipo-pam™.” In addition, a next-generation immunotherapy candidate, “CTRNA-001,” which is based on mRNA-lipid nanoparticle (LNP) technology, has been selected for the national new drug development program, and a new candidate is in development.

This investment is expected to not only provide funding but also enhance Aribio Lab’s strategic standing within the group. In particular, with Aribio becoming the largest shareholder and Aribio Holdings securing the position of second-largest shareholder, it is interpreted that the group’s intention to position Aribio Lab as a core bio hub in the vaccine, immunity, and mRNA sectors has become clearer.

If Aribio’s experience in global clinical trials with AR1001 combines with Aribio Lab’s vaccine, immunity, and mRNA platforms, the scope of R&D collaboration will likely expand. As the pipeline extends from Alzheimer’s treatment to vaccines and immunotherapies, Aribio Lab’s R&D capabilities and business role within the group are also expected to grow.

This content was produced with the assistance of AI translation services.